• Vaccine Name: SL3261-L. major
• Target Pathogen: Leishmania major
• Target Disease: Cutaneous leishmaniasis
• Vaccine Ontology ID: VO_0004671
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Host Species as Laboratory Animal Model: mouse
• KMP-11 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Antigens were differentially expressed on the surface or in the cytosol of Salmonella typhimurium SL3261 (Schroeder et al., 2011).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001031
• Preparation: Salmonella expressing the novel Leishmania antigens LinJ08.1190 and LinJ23.0410 (Schroeder et al., 2011)
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Mice were vaccinated with a single dose of Salmonella vaccine strains, the carrier control SL3261 or treated with PBS (Schroeder et al., 2011).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: Mice were subsequently challenged with 2×10^6 late-stationary phase L. major promastigotes into the left hind footpad (Schroeder et al., 2011).
• Efficacy: We show that vaccine strains of Salmonella expressing the novel Leishmania antigens LinJ08.1190 and LinJ23.0410 significantly reduced visceralisation of L. major and enhanced systemic resistance against L. donovani in susceptible BALB/c mice (Schroeder et al., 2011).